Welcome to Ash 2020. This is the first in a series of videos that I'm going to put out about the biggest and best abstracts at Ash. And if you have suggestions, you can go ahead and email Plenary Session Podcast at gmail.com. Today I'm going to be talking about talquitamab, a T-cell directing GPRC 5D by specific antibody for my favorite disease multiple myeloma. In the last few weeks, Plenary

Session has done a couple of very interesting videos on myeloma. We featured the Raj

Kumar Goodman debate about should I treat smoldering. And also, I gave a talk to the UK

Myeloma Group. I have just had a chance to read this paper. I've read the supplement.

This is the first of hopefully many abstracts that I'm going to be bringing you in these amateur videos that are not produced with my usual setup. So please forgive that. All right, let's get into it, GPRC 5D. But first, two announcements. Number one, don't hang a bag on my door full of garbage. Okay, I just have to recycle this for you. You're killing trees and nobody

wants to read this. Okay, that's number one. Number two, junior faculty, stop doing the ad boards.

You're getting paid a triviality of the amount of money the company is making by persuading you.

The company's goal is not actually to solicit your feedback. It's very unlikely you're able to

tell them something they don't already know. They are soliciting you because they want your allegiance.

And that's what that token payment is for.

So don't do it.

All right, Taquitamab.

Let's get into this.

This is GPRC 5D.

Ah, the second one.

Of course, Miling Cody at all, GPRC 5D.

Carty was the first one.

This is the bite. Jansen's bite. The rich get rich are over at Jansen. They got a, they got another product likely coming to market.

Here's what they write in the introduction. They talk about the dire state of triple refractory myeloma.

It's actually not that dire because if you have triple refractory myeloma, there are many, many, many other drugs that you could take and that might even benefit you based on randomized studies.

There's penta refractory, which we could say is actually a little bit worse.

And then really when you talk about people who are refractory to seven prior lines and beyond, then I'll give you credit.

...